SIM0500

Phase 1Small molecule

Jiangsu Simcere Pharmaceutical Co., Ltd.

SIM0500 is one of 10 small molecule programs targeting Relapsed or Refractory Multiple Myeloma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or Refractory Multiple MyelomaRecruiting

Relapsed or Refractory Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Relapsed or Refractory Multiple Myeloma

#DrugCompanyPhaseTrials

Darzalex

Johnson & Johnson

Phase 3

3 2

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3 3

Etentamig

AbbVie

Phase 3

1 4

Actemra

CCelltrion

Phase 1

1 5

Elranatamab

Pfizer

Phase 1

1 6

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 7

Cevostamab

Roche

Phase 1

1 8

SG301

HHangzhou Sumgen Biotech Co., Ltd.

Phase 1

1 9

JNJ-79635322

Johnson & Johnson

Phase 1

1 10

SIM0500

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Relapsed or Refractory Multiple Myeloma

NCT06375044

Clinical

Trials by Indication[1]

Relapsed or Refractory Multiple Myeloma1 trial

A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT06375044·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SIM0500. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SIM0500 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SIM0500. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Simcere Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Jiangsu Simcere Pharmaceutical Co., Ltd.

SIM0500

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Relapsed or Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News